Gennaro Balenzano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gennaro Balenzano has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Nunzio Denora
Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70125 Bari, Italy
3 shared publications Giuseppe Francesco Racaniello
2 shared publications- Valentino Laquintana
Department of Pharmacy-Drug Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy
2 shared publications - Andreas Bernkop-Schnürch
Department of Pharmaceutical Technology Institute of Pharmacy University of Innsbruck Innsbruck Austria
1 shared publication Angela Assunta Lopedota
Department of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Via E. Orabona, 4, I-70125 Bari, Italy
1 shared publication- Angela Assunta Lopedota
Department of Pharmacy-Pharmaceutical Sciences, University of Bari Aldo Moro, 70125 Bari, Italy
1 shared publication
Latest Publications
- Open Access
- 5 March 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 95
S-protected thiolated surfactants enhancing surface properties of lipid-based nanocarriers
- 5 March 2024
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 95
Open AccessS-protected thiolated surfactants enhancing surface properties of lipid-based nanocarriers
- Open Access
- 16 February 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (2) , 277
Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy
Cataract surgery interventions are constantly increasing, particularly among adult and elderly patients. This type of surgery can lead to inflammatory states of the ocular anterior segment (AS), usually healed via postoperative treatment with dexamethasone (DEX)-containing eye drops. The application of eye drops is challenging due to the high number of daily administrations. In this study, mucoadhesive nanoparticles (NPs) were formulated to improve the residence time of DEX on the corneal mucosa, enhancing the drug’s solubility and bioavailability. The NPs were generated using an ionotropic gelation technique, exploiting the interaction between the cationic group of chitosan (CS) and the anionic group of sulfobutylether-β-cyclodextrin (SBE-β-CD). The formation of the inclusion complex and its stoichiometry were studied through phase solubility studies, Job’s plot method, and Bi-directional transport studies on MDCKII-MDR1. The obtained NPs showed good chemical and physical characteristics suitable for drug loading and subsequent testing on animal mucosa. The DEX-loaded CS/SBE-β-CD NPs exhibited a prolonged residence time on animal mucosa and demonstrated enhanced drug permeability through the corneal membrane, showing a sustained release profile. The developed NPs posed no irritation or toxicity concerns upon local administration, making them an optimal and innovative drug delivery system for inflammatory AS diseases treatment.
- 16 February 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (2) , 277
Open AccessChitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy
Cataract surgery interventions are constantly increasing, particularly among adult and elderly patients. This type of surgery can lead to inflammatory states of the ocular anterior segment (AS), usually healed via postoperative treatment with dexamethasone (DEX)-containing eye drops. The application of eye drops is challenging due to the high number of daily administrations. In this study, mucoadhesive nanoparticles (NPs) were formulated to improve the residence time of DEX on the corneal mucosa, enhancing the drug’s solubility and bioavailability. The NPs were generated using an ionotropic gelation technique, exploiting the interaction between the cationic group of chitosan (CS) and the anionic group of sulfobutylether-β-cyclodextrin (SBE-β-CD). The formation of the inclusion complex and its stoichiometry were studied through phase solubility studies, Job’s plot method, and Bi-directional transport studies on MDCKII-MDR1. The obtained NPs showed good chemical and physical characteristics suitable for drug loading and subsequent testing on animal mucosa. The DEX-loaded CS/SBE-β-CD NPs exhibited a prolonged residence time on animal mucosa and demonstrated enhanced drug permeability through the corneal membrane, showing a sustained release profile. The developed NPs posed no irritation or toxicity concerns upon local administration, making them an optimal and innovative drug delivery system for inflammatory AS diseases treatment.
- Open Access
- 24 October 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 647, 123553
Cyclodextrin-based supramolecular deep eutectic solvent (CycloDES): A vehicle for the delivery of poorly soluble drugs
- 24 October 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 647, 123553
Open AccessCyclodextrin-based supramolecular deep eutectic solvent (CycloDES): A vehicle for the delivery of poorly soluble drugs